885 related articles for article (PubMed ID: 21388062)
1. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of p75 neurotrophin receptor (p75NTR) as a marker of breast myoepithelial cells.
Popnikolov NK; Cavone SM; Schultz PM; Garcia FU
Mod Pathol; 2005 Dec; 18(12):1535-41. PubMed ID: 16258511
[TBL] [Abstract][Full Text] [Related]
3. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
Reis-Filho JS; Steele D; Di Palma S; Jones RL; Savage K; James M; Milanezi F; Schmitt FC; Ashworth A
Mod Pathol; 2006 Feb; 19(2):307-19. PubMed ID: 16424897
[TBL] [Abstract][Full Text] [Related]
4. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries.
Gould VE; Mosquera JM; Leykauf K; Gattuso P; Dürst M; Alonso A
Hum Pathol; 2005 May; 36(5):536-45. PubMed ID: 15948121
[TBL] [Abstract][Full Text] [Related]
5. Cellular expression of growth hormone and prolactin receptors in human breast disorders.
Mertani HC; Garcia-Caballero T; Lambert A; Gérard F; Palayer C; Boutin JM; Vonderhaar BK; Waters MJ; Lobie PE; Morel G
Int J Cancer; 1998 Apr; 79(2):202-11. PubMed ID: 9583737
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-kit proto-oncogene product in breast tissue.
Yared MA; Middleton LP; Meric F; Cristofanilli M; Sahin AA
Breast J; 2004; 10(4):323-7. PubMed ID: 15239791
[TBL] [Abstract][Full Text] [Related]
7. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status.
Tsuura Y; Suzuki T; Honma K; Sano M
J Cancer Res Clin Oncol; 2002 May; 128(5):239-46. PubMed ID: 12029439
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.
Werling RW; Hwang H; Yaziji H; Gown AM
Am J Surg Pathol; 2003 Jan; 27(1):82-90. PubMed ID: 12502930
[TBL] [Abstract][Full Text] [Related]
9. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
11. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma.
Abdel-Fatah TM; Powe DG; Hodi Z; Lee AH; Reis-Filho JS; Ellis IO
Am J Surg Pathol; 2007 Mar; 31(3):417-26. PubMed ID: 17325484
[TBL] [Abstract][Full Text] [Related]
12. Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions.
Kuroda N; Jin YL; Hamauzu T; Toi M; Miyazaki E; Hiroi M; Moriki T; Enzan H
Histol Histopathol; 2005 Jul; 20(3):707-12. PubMed ID: 15944918
[TBL] [Abstract][Full Text] [Related]
13. Standardized in situ AgNOR analysis in breast pathology: diagnostic and cell kinetic implications.
Bànkfalvi A; Ofner D; Schmid KW; Schmitz KJ; Breukelmann D; Krech R; Böcker W
Pathol Res Pract; 1999; 195(4):219-29. PubMed ID: 10337659
[TBL] [Abstract][Full Text] [Related]
14. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation.
Bratthauer GL; Saenger JS; Strauss BL
Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199
[TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
[TBL] [Abstract][Full Text] [Related]
16. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions.
Barth PJ; Ebrahimsade S; Ramaswamy A; Moll R
Virchows Arch; 2002 Mar; 440(3):298-303. PubMed ID: 11889601
[TBL] [Abstract][Full Text] [Related]
17. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions.
Chauhan H; Abraham A; Phillips JR; Pringle JH; Walker RA; Jones JL
J Clin Pathol; 2003 Apr; 56(4):271-6. PubMed ID: 12663638
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions.
Bier B; Douglas-Jones A; Tötsch M; Dockhorn-Dworniczak B; Böcker W; Jasani B; Schmid KW
Breast Cancer Res Treat; 1994; 30(3):213-21. PubMed ID: 7981441
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
20. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
